Mammotome, a Danaher company, has received the CE mark for its HydroMARK™ Plus Breast Biopsy Site Marker. This approval allows wider access to the innovative marker technology across Europe, benefiting patients undergoing breast cancer diagnosis and treatment. The HydroMARK Plus combines proprietary hydrogel technology with features that enhance marker stability and visibility in breast care, supporting improved clinical outcomes.
The global ovarian cancer diagnostics market is projected to grow from $4.92 billion in 2025 to $8.08 billion by 2035, at a CAGR of 5.06%. Growth is fueled by rising ovarian cancer cases, increased adoption of AI-powered imaging, biomarker testing, a...
The global automated liquid handling systems market was valued at $2.7 billion in 2025 and is projected to grow to $6.9 billion by 2035, with a compound annual growth rate (CAGR) of 9.8%. This growth is driven by increasing pharmaceutical and biotech...
